CIK 0001649904 · Large accelerated filer
RHYTHM PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- RYTM
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 462159271
- Phone
- 857-264-4280
- Business address
- 222 BERKELEY STREET, 12TH FLOOR, BOSTON, MA, 02116
- Former names
- RHYTHM METABOLIC, INC.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $11,753,355
- in 2 filings, $11.8M under 10b5-1 plans
Net −$11,753,355. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-02-14 | Meeker David P President and CEO | Grant or award · Restricted Stock Units 10b5-1 | +133,350 | 133,350 | ||
| 2025-02-14 | Meeker David P President and CEO | Grant or award · Stock Options (Right to Buy) 10b5-1 | +200,000 | 200,000 | ||
| 2025-02-14 | Mazabraud Yann EVP, Head of International | Grant or award · Restricted Stock Units | +40,000 | 40,000 | ||
| 2025-02-14 | Mazabraud Yann EVP, Head of International | Grant or award · Stock Options (Right to Buy) | +60,000 | 60,000 | ||
| 2025-02-14 | Lee Jennifer Kayden EVP, Head of North America | Grant or award · Restricted Stock Units 10b5-1 | +36,650 | 36,650 | ||
| 2025-02-14 | Lee Jennifer Kayden EVP, Head of North America | Grant or award · Stock Options (Right to Buy) 10b5-1 | +55,000 | 55,000 | ||
| 2025-02-14 | German Christopher Paul Corporate Controller & CAO | Grant or award · Restricted Stock Units | +7,225 | 7,225 | ||
| 2025-02-14 | German Christopher Paul Corporate Controller & CAO | Grant or award · Stock Options (Right to Buy) | +5,400 | 5,400 | ||
| 2025-02-14 | Garfield Alastair Chief Scientific Officer | Grant or award · Restricted Stock Units | +26,650 | 26,650 | ||
| 2025-02-14 | Garfield Alastair Chief Scientific Officer | Grant or award · Stock Options (Right to Buy) | +40,000 | 40,000 | ||
| 2025-02-14 | Cramer Pamela J. Chief Human Resources Officer | Grant or award · Restricted Stock Units 10b5-1 | +20,000 | 20,000 | ||
| 2025-02-14 | Cramer Pamela J. Chief Human Resources Officer | Grant or award · Stock Options (Right to Buy) 10b5-1 | +30,000 | 30,000 | ||
| 2025-02-13 | Lee Jennifer Kayden EVP, Head of North America | Sale 10b5-1 | −1,205 | $58.00 | $70K | 2,393 |
| 2025-02-12 | Smith Hunter C Chief Financial Officer | Sale 10b5-1 | −739 | $56.39 | $42K | 105,556 |
| 2025-02-12 | Smith Hunter C Chief Financial Officer | Sale 10b5-1 | −12 | $56.22 | $675 | 105,544 |
| 2025-02-12 | Shulman Joseph Chief Technical Officer | Sale 10b5-1 | −462 | $56.39 | $26K | 5,619 |
| 2025-02-12 | Shulman Joseph Chief Technical Officer | Sale 10b5-1 | −7 | $57.09 | $400 | 5,612 |
| 2025-02-12 | Lee Jennifer Kayden EVP, Head of North America | Sale 10b5-1 | −600 | $56.39 | $34K | 4,813 |
| 2025-02-12 | Lee Jennifer Kayden EVP, Head of North America | Sale 10b5-1 | −10 | $56.41 | $564 | 4,803 |
| 2025-02-12 | Lee Jennifer Kayden EVP, Head of North America | Sale 10b5-1 | −1,205 | $56.39 | $68K | 3,598 |
Page 18 of 19 · 376 trades